EGFR and metastatic colorectal cancer: To date, of the anti-EGFR monoclonal antibodies (mAbs), only cetuximab and panitumumab have been approved for the treatment of patients with metastatic colorectal cancer (mCRC) with RAS wild-type status [4–8].